Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 193
Inquire Before Buying
This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 13, 4, 1, 17 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018

Table of Contents
Table of Contents 2
Introduction 5
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 6
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 7
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 17
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 25
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 38
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 163
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 169
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 172
Appendix 187

List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by DalCor Pharmaceuticals Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Livzon Pharmaceutical Group Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Orion Corporation, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Reven Pharmaceuticals Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by XyloCor Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018 (Contd..2), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018 (Contd..3), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2018 (Contd..1), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2018 (Contd..2), H2 2018

List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • 2018-2023 Global Atorvastatin Calcium Consumption Market Report
    Published: 17-Jul-2018        Price: US 4660 Onwards        Pages: 165
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Atorvastatin Calcium market for 2018-2023. Atorvastatin calcium is a pharmaceutical raw material in the production of atorvastatin calcium drug (trade name: Lipitor), which is a prescription medicine that lowers the LDL cholesterol and triglycerides in the blood and can raise HDL cholesterol as well. Atorvastatin calcium usually is white powder and whose CA......
  • 2018 Top 5 Atorvastatin Calcium Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 17-Jul-2018        Price: US 4960 Onwards        Pages: 142
    Atorvastatin calcium is a pharmaceutical raw material in the production of atorvastatin calcium drug (trade name: Lipitor), which is a prescription medicine that lowers the LDL cholesterol and triglycerides in the blood and can raise HDL cholesterol as well. Atorvastatin calcium usually is white powder and whose CAS number is 134523-03-8. Atorvastatin calcium refers to a pharmaceutical raw material in the production of atorvastatin calcium drug. It contains chemical synthesis type and bio......
  • 2018-2023 Global Rosuvastatin Calcium Consumption Market Report
    Published: 17-Jul-2018        Price: US 4660 Onwards        Pages: 163
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Rosuvastatin Calcium market for 2018-2023. Rosuvastatin calcium (CAS 147098-20-2, molecular formula being C44H54CaF2N6O12S2) is the active pharmaceutical ingredient for the once-a-day dyslipidaemia treatment Crestor, it is one approved API which can be used to reduce the risk of heart attack and stroke.Rosuvastatin calcium is a hygroscopic powder suitable f......
  • 2018 Top 5 Rosuvastatin Calcium Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 17-Jul-2018        Price: US 4960 Onwards        Pages: 142
    Rosuvastatin calcium (CAS 147098-20-2, molecular formula being C44H54CaF2N6O12S2) is the active pharmaceutical ingredient for the once-a-day dyslipidaemia treatment Crestor, it is one approved API which can be used to reduce the risk of heart attack and stroke.Rosuvastatin calcium is a hygroscopic powder suitable for the manufacture of tablets and capsules. The appropriate excipients need to be added. The particle size of the product is designed in such a way that optimal dissolution can be obta......
  • Hypotension - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 44
    Hypotension - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H2 2018, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms i......
  • Thromboembolism - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 98
    Thromboembolism - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape. When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the che......
  • Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 43
    Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2018, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape. Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly ......
  • Ischemia Reperfusion Injury - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 152
    Ischemia Reperfusion Injury - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2018, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape. Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nut......
  • Dilated Cardiomyopathy - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 65
    Dilated Cardiomyopathy - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H2 2018, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and we......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs